News | October 19, 2012

Boston Scientific to Acquire Rhythmia Medical’s EP Mapping, Navigation Technology

October 19, 2012 — Boston Scientific Corp. entered into a definitive agreement to acquire privately-held Rhythmia Medical Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology (EP) procedures, including atrial fibrillation and atrial flutter. Rhythmia Medical is based in Burlington, Mass. The transaction was expected to close Oct. 12.

"The acquisition of Rhythmia Medical is a decisive step forward for Boston Scientific in the electrophysiology ablation business, including the high-growth segment of complex ablation," said Hank Kucheman, CEO of Boston Scientific. "Electrophysiology is a $2.5 billion market and growing at a double-digit pace, representing a key growth opportunity for us. Rhythmia Medical has a strong and impressive team, and its technology is expected to add innovation and breadth to Boston Scientific's suite of solutions in this strategically important space."

Atrial fibrillation is a disorder that disrupts the ability of the heart to beat regularly and pump blood efficiently. Approximately 15 million people worldwide are affected. Catheter ablation enabled by 3-D mapping and navigation is commonly used to treat many heart rhythm disorders, including atrial flutter and atrial fibrillation.

"Rhythmia Medical's revolutionary mapping technology is expected to significantly enhance physician treatment options and ultimately facilitate and improve what today are long and complicated procedures," said Doron Harlev, co-founder and co-CEO of Rhythmia Medical. "Our system is expected to become a very promising tool for physicians to treat patients with complex cardiac arrhythmias. We are excited to combine our mapping system with Boston Scientific's strong catheter platform and commercialization capabilities."

Once the mapping system is cleared by the U.S. Food and Drug Administration (FDA) and receives CE mark approval in Europe, Boston Scientific expects to begin a limited market launch of the system in 2013 and a full market launch in 2014.

The agreement calls for an upfront payment of $90 million payable upon transaction closing, and up to an additional $175 million in contingent payments based on regulatory, commercial and sales-based milestones through 2017. Boston Scientific currently expects the net impact of this transaction on adjusted earnings per share to be immaterial for years 2013 and 2014 and break even to accretive thereafter, and more dilutive on a GAAP basis as a result of acquisition-related net charges and amortization, which will be determined during the fourth quarter.

For more information: www.bostonscientific.com

Related Content

Computer Simulations May Treat Most Common Heart Rhythm Disorder

The OPTIMA (Optimal Target Identification via Modelling of Arrhythmogenesis) simulator uses contrast-enhanced MRI scans to create personalized digital replicas of a patient's heart to guide catheter abation for atrial fibrillation. Image courtesy of Patrick M. Boyle and Natalia A. Trayanova.

News | EP Mapping and Imaging Systems | August 19, 2019
Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper chambers of the heart...
Charge Density Mapping Eliminates Repeat Ablation for Atrial Fibrillation at One Year
News | EP Mapping and Imaging Systems | July 15, 2019
Acutus Medical announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology. The...
Innovative Health Receives FDA Clearance to Reprocess Pentaray Nav Eco High-density Mapping Catheter
News | EP Mapping and Imaging Systems | July 05, 2019
Single-use cardiology medical device reprocessing company Innovative Health, received U.S. Food and Drug Administration...
VIVO 3-D Cardiac Mapping System Cleared by FDA
Technology | EP Mapping and Imaging Systems | July 01, 2019
Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO (View into...
Algorithm Steers Catheters to Right Spot to Treat Atrial Fibrillation

Using human AFib simulations, the researchers demonstrated that their technique can stop the catheter at the right target and identify the source type with a 95.25 percent success rate. This new algorithm also is effective in scarred tissue, which makes ablation more challenging, and has a 99 percent detection rate regardless of the scar size. Image courtesy of Florida Atlantic University.

News | EP Mapping and Imaging Systems | May 28, 2019
Researchers have developed the first algorithm that can locate patient-specific ablation targets for atrial...
Acutus Medical Announces Rhythm Xience Acquisition, New Partnerships at HRS 2019

Acutus Medical's acquisition of Rhythm Xience brings the Flextra steerable introducer sheath into Acutus Medical's product portfolio.

News | EP Mapping and Imaging Systems | May 17, 2019
At the 40th annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Acutus Medical announced the agreement...
Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Feature | EP Mapping and Imaging Systems | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial
Philips and Medtronic Collaborate on Image-guided Atrial Fibrillation Treatment
News | EP Mapping and Imaging Systems | May 09, 2019
Philips announced a collaboration with Medtronic to further advance treatment of paroxysmal atrial fibrillation (PAF),...
Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform
Technology | EP Mapping and Imaging Systems | April 26, 2019
Acutus Medical announced U.S. Food and Drug Administration (FDA) clearance of its second-generation AcQMap platform,...
Acutus AcQMap Imaging System Helps Eliminate Arrhythmia With Single Ablation
News | EP Mapping and Imaging Systems | January 28, 2019
Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac...
Overlay Init